Levi & Korsinsky Unveils Timeline of Alleged Misrepresentations in Vistagen Therapeutics' Securities Class Action

Introduction

In recent developments, Levi & Korsinsky, LLP has announced crucial timelines regarding the alleged misrepresentations in Vistagen Therapeutics, Inc. (NASDAQ: VTGN) securities class action. This timeline serves as a significant touchpoint for investors who have faced losses in this case. The firm is urging affected investors to act quickly, as the deadline for lead plaintiff status is fast approaching.

Who is Affected?

Investors who purchased Vistagen securities between April 1, 2024, and December 16, 2025, may be entitled to recover damages. If you find yourself among this group, now is the time to discuss your options with specialized attorneys at Levi & Korsinsky. Joseph E. Levi, Esq. can be contacted directly at (212) 363-7500 for more personalized legal advice.

Key Dates in the Timeline

April 1, 2024 — Class Period Commences

Vistagen Therapeutics initiated a pivotal moment by announcing the enrollment of the first patient in its PALISADE-3 Phase 3 trial. This was celebrated by management as a "major milestone" in the developmental roadmap for their promising drug candidate.

June 11, 2024 — Fiscal Year Results

The fiscal year results were shared, where Chief Operating Officer Joshua Prince introduced “notable enhancements” aimed at optimizing the quality of trial enrollment. These improvements included in-person investigator meetings and meticulous training sessions designed to ensure compliance and efficiency.

November 3, 2025 — Trial Completion

A breakthrough was reported as the company announced the completion of the Phase 3 public speaking challenge study. While the management expressed optimism about the findings and the drug candidate’s potential, the challenges that lay ahead were still evident.

December 17, 2025 — Corrective Disclosure

In a surprising turn of events, the company disclosed that the Phase 3 study did not yield statistically significant improvements on the primary endpoint. This shocker was characterized as "unexpected" by management, contradicting the previously positive outcomes noted in earlier studies. This announcement raised substantial concerns among investors and stakeholders alike.

How to Proceed

Given the volatility and the intricate nature of the current situation, it’s imperative for interested parties to check their eligibility to participate in this ongoing class action. Levi & Korsinsky is positioning itself as a strong ally for those affected, prepared to navigate the complexities of securities litigation on their behalf.

About Levi & Korsinsky, LLP

Levi & Korsinsky boasts over two decades of experience in securing substantial settlements for aggrieved shareholders. Their track record includes securing hundreds of millions of dollars in various cases, making them a formidable contender in the field of complex securities litigation. Consistently ranked in ISS’s Top 50 Report, they have cultivated a team of over 70 specialists dedicated to serving their clients’ needs efficiently and competently.

Conclusion

The situation surrounding Vistagen Therapeutics is evolving, and time is of the essence for those impacted. Levi & Korsinsky is encouraging swift action from investors to ensure that they can possibly restore their financial standing through participation in the class action. Keep an eye on the deadlines and gather necessary documentation to bolster your case as you reach out for professional assistance.